Antibody Sustainability in SARS-CoV-2 Healthcare Professionals' Patient Cohort
In this study, it was aimed to evaluate one-year follow-up of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) specific antibodies formed against the virus binding site, in a coronavirus disease-2019 (COVID-19) positive case cohort (n= 413) between the period March 2020 to December 2020 in Manisa Celal Bayar University Hospital, until July 2021. SARS-CoV-2 antibodies were determined by the chemiluminescent enzyme immunoassay (CLIA) method. Values of 1.0 and above were considered positive. Chi-square tests and Joinpoint regression analysis (version 4.7.0) were used in the statistical analyses. The mean age of the participants was 34.9 ± 9.3 and 60.2% of them were women. Between 21-30 days after the diagnosis of COVID-19, total antibody level was above the threshold value in 72.2% (n= 126) of the participants, while this rate increased to 79.1% (n= 240) in 31-60 day interval. In the following period, this rate decreased to 38.8% (n= 108) in days 211st to 240th. Antibody response could not be detected in 76 (20.7%) of 367 employees who have initially been followed up. The percentage of total antibody positivity prevalence ranged from 98.9% to 96.1% in the 31-210th day after diagnosis, in the follow-up of 291 employees whose total antibody positivity was detected after diagnosis. According to the results of the Joinpoint regression analysis, after the diagnosis of COVID-19, the curve showing the percentage of antibody positivity was broken at two points: The first breaking point was observed in 181-210th days (6-7 months) (p= 0.069), and the second breaking point was in 271-300th days (9-10 months) (p< 0.001). As a result, the highest antibody positivity rates were detected after the 30th day of the disease onset and antibody positivity was maintained in the first seven months after diagnosis; the antibody positivity rate decreased to 25% at the end of the first year.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
---|---|
Enthalten in: |
Mikrobiyoloji bulteni - 56(2022), 2 vom: 27. Apr., Seite 274-287 |
Sprache: |
Türkisch |
---|
Weiterer Titel: |
Sağlık Çalışanları SARS-CoV-2 Hasta Kohordunda Antikor Sürdürülebilirliği |
---|
Beteiligte Personen: |
Eser, Erhan [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 29.04.2022 Date Revised 29.04.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.5578/mb.20229807 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM34006174X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM34006174X | ||
003 | DE-627 | ||
005 | 20231226004309.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||tur c | ||
024 | 7 | |a 10.5578/mb.20229807 |2 doi | |
028 | 5 | 2 | |a pubmed24n1133.xml |
035 | |a (DE-627)NLM34006174X | ||
035 | |a (NLM)35477230 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a tur | ||
100 | 1 | |a Eser, Erhan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Antibody Sustainability in SARS-CoV-2 Healthcare Professionals' Patient Cohort |
246 | 3 | 3 | |a Sağlık Çalışanları SARS-CoV-2 Hasta Kohordunda Antikor Sürdürülebilirliği |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.04.2022 | ||
500 | |a Date Revised 29.04.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a In this study, it was aimed to evaluate one-year follow-up of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) specific antibodies formed against the virus binding site, in a coronavirus disease-2019 (COVID-19) positive case cohort (n= 413) between the period March 2020 to December 2020 in Manisa Celal Bayar University Hospital, until July 2021. SARS-CoV-2 antibodies were determined by the chemiluminescent enzyme immunoassay (CLIA) method. Values of 1.0 and above were considered positive. Chi-square tests and Joinpoint regression analysis (version 4.7.0) were used in the statistical analyses. The mean age of the participants was 34.9 ± 9.3 and 60.2% of them were women. Between 21-30 days after the diagnosis of COVID-19, total antibody level was above the threshold value in 72.2% (n= 126) of the participants, while this rate increased to 79.1% (n= 240) in 31-60 day interval. In the following period, this rate decreased to 38.8% (n= 108) in days 211st to 240th. Antibody response could not be detected in 76 (20.7%) of 367 employees who have initially been followed up. The percentage of total antibody positivity prevalence ranged from 98.9% to 96.1% in the 31-210th day after diagnosis, in the follow-up of 291 employees whose total antibody positivity was detected after diagnosis. According to the results of the Joinpoint regression analysis, after the diagnosis of COVID-19, the curve showing the percentage of antibody positivity was broken at two points: The first breaking point was observed in 181-210th days (6-7 months) (p= 0.069), and the second breaking point was in 271-300th days (9-10 months) (p< 0.001). As a result, the highest antibody positivity rates were detected after the 30th day of the disease onset and antibody positivity was maintained in the first seven months after diagnosis; the antibody positivity rate decreased to 25% at the end of the first year | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
700 | 1 | |a Şenol Akar, Şebnem |e verfasserin |4 aut | |
700 | 1 | |a Akçalı, Sinem |e verfasserin |4 aut | |
700 | 1 | |a Ecemiş, Talat |e verfasserin |4 aut | |
700 | 1 | |a Erbay Dündar, Pınar |e verfasserin |4 aut | |
700 | 1 | |a Çiçek, Kübra |e verfasserin |4 aut | |
700 | 1 | |a Akman, Damla |e verfasserin |4 aut | |
700 | 1 | |a Tüzün, Ecem |e verfasserin |4 aut | |
700 | 1 | |a Şanlı Erkekoğlu, Gülsüm |e verfasserin |4 aut | |
700 | 1 | |a Buran, Zeynep Ceyda |e verfasserin |4 aut | |
700 | 1 | |a Öztürk Arıkan, Zeynep Öykü |e verfasserin |4 aut | |
700 | 1 | |a Karadağ Yalçın, Ferya |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Mikrobiyoloji bulteni |d 1993 |g 56(2022), 2 vom: 27. Apr., Seite 274-287 |w (DE-627)NLM000074748 |x 0374-9096 |7 nnns |
773 | 1 | 8 | |g volume:56 |g year:2022 |g number:2 |g day:27 |g month:04 |g pages:274-287 |
856 | 4 | 0 | |u http://dx.doi.org/10.5578/mb.20229807 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 56 |j 2022 |e 2 |b 27 |c 04 |h 274-287 |